Events and Presentations

Nabriva Therapeutics Added to NASDAQ Biotechnology Index

Events and Presentations | Investor News | Shareholder Information
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006
Press Releases
DateTitle  
12/13/17Nabriva Therapeutics Added to NASDAQ Biotechnology Index
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 13, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that it has been selected for addition to the NASDAQ Biotechnology Index®, which will become effective prior to the open of U.S. markets on Monday, December 18, 2017. ... 
 Printer Friendly Version
12/04/17Nabriva Therapeutics Announces Completion of Enrollment in LEAP 2, a Phase 3 Clinical Trial Evaluating Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia in Adults
Company remains on track to report topline results in Spring 2018 DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that it has completed enrollment in its second lefamulin evaluation against pneumonia (LEAP 2) Phase... 
 Printer Friendly Version
11/30/17Nabriva Therapeutics to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that members of the company’s management team will participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference on Wednesday, December 13, 2017. Th... 
 Printer Friendly Version
11/09/17Nabriva Therapeutics Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights
- Positive topline results from pivotal LEAP 1 trial announced in September, with read-out from second Phase 3 trial, LEAP 2, expected in the spring of 2018 - - $112.7 million cash and investments as of September 30, 2017 - DUBLIN, Ireland, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin cl... 
 Printer Friendly Version
10/25/17Nabriva Therapeutics to Present at the Stifel 2017 Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the research and development of new medicines to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Chief Executive Officer Colin Broom, M.D., will provide a company overview, including the previously released lefamulin evaluation against pneumonia (LEAP 1) Phase 3 trial topline results, an... 
 Printer Friendly Version
09/28/17Nabriva Therapeutics to Present Lefamulin Data at ID Week 2017
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept. 28, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that it will showcase data at ID Week 2017 taking place from October 4-8 in San Diego, California. At the meeting, three presentations will feature the company’s m... 
 Printer Friendly Version
09/20/17Nabriva Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the research and development of new medicines to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Chief Executive Officer Colin Broom, M.D., will provide a company overview, including the previously released lefamulin evaluation against pneumonia (LEAP 1) Phase 3 trial topline results, a... 
 Printer Friendly Version
09/19/17Nabriva Therapeutics Announces Pricing of Public Offering of Ordinary Shares of Approximately $80 Million
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV) today announced the pricing of its underwritten public offering of 9,411,765 ordinary shares at a public offering price of $8.50 per share. In addition, Nabriva Therapeutics has granted the underwriters an option for a period of 30 days to purchase up to an additional 1,411,764 ordinary shares at the public offering price, less the underwriting discounts and commissions. All of t... 
 Printer Friendly Version
09/18/17Nabriva Therapeutics Announces Proposed Public Offering of Ordinary Shares
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV) today announced that it has commenced an underwritten public offering of $80.0 million of ordinary shares. In addition, Nabriva Therapeutics expects to grant the underwriters an option for a period of 30 days to purchase up to an additional $12.0 million of ordinary shares at the public offering price, less the underwriting discounts and commissions. All of the ordinary shares in... 
 Printer Friendly Version
09/18/17Nabriva Therapeutics Announces Positive Topline Results from Global, Phase 3 Clinical Trial Evaluating IV and Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia
- Lefamulin met all primary FDA and EMA endpoints with a favorable tolerability profile -   - Conference call and webcast today at 8:30 a.m. EDT to review results - DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announc... 
 Printer Friendly Version
08/31/17Nabriva Therapeutics Announces Resignation of Elyse Seltzer, M.D.
Colin Broom, M.D. to serve as interim chief medical officer DUBLIN, Ireland and KING OF PRUSSIA, Pa., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Elyse Seltzer, M.D., has decided to resign from her position as chief medical officer effective as of... 
 Printer Friendly Version
08/07/17Nabriva Therapeutics Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights
Expects top-line data from LEAP 1 CABP Phase 3 trial in September 2017 and from LEAP 2 CABP Phase 3 trial in the first quarter 2018 DUBLIN, Ireland, Aug. 07, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today provided a business and clinical development update and reported its ... 
 Printer Friendly Version
08/02/17Nabriva Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the research and development of new medicines to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Gary Sender, Chief Financial Officer of Nabriva Therapeutics plc, will provide a company overview and business update at the 2017 Wedbush PacGrow Healthcare Conference on Wednesday, August 16... 
 Printer Friendly Version
07/11/17Nabriva Therapeutics Appoints Francesco Maria Lavino as Chief Commercial Officer
Further Strengthens Management Team of Industry Veterans to Support Commercialization of Potential New Antibiotic for Community-Acquired Bacterial Pneumonia DUBLIN, Ireland and KING OF PRUSSIA, Pa., July 11, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the research and development of new medicines to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced the appointment of Francesco Maria Lav... 
 Printer Friendly Version
06/26/17Nabriva Therapeutics Appoints Carrie Bourdow and Colin Broom to the Board
DUBLIN, Ireland, June 26, 2017 – Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced the appointment of Carrie Bourdow, Senior Vice President and Chief Commercial Officer of Trevena, Inc., to the Company’s Board of Directors. With the completion of the Company’s redom... 
 Printer Friendly Version
06/26/17Nabriva Therapeutics plc Successfully Concludes Tender Offer for Outstanding Common Shares of Nabriva Therapeutics plc and Outstanding American Depositary Shares of Nabriva Therapeutics plc
DUBLIN, Ireland, June 26, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc ("Nabriva Therapeutics") today announced that it has successfully concluded its previously announced tender offer related to the exchange of common shares ("Nabriva AG Common Shares") of Nabriva Therapeutics plc ("Nabriva AG") and American depositary shares of Nabriva AG (NASDAQ:NBRV) ("Nabriva AG ADSs") for ordinary shares ("Nabriva Ireland Shares") of Nabriva Therapeutics (the "Exchange Offer").  The Exchange Of... 
 Printer Friendly Version
06/05/17Nabriva Therapeutics Announces Webcast of Analyst & Investor Day on June 19, 2017
VIENNA, Austria and KING OF PRUSSIA, Pa., June 05, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that the Company will webcast its Analyst & Investor Day being held from 9:30 a.m. to 1:30 p.m. ET on June 19, 2017 in New York City. Nabriva will provide an over... 
 Printer Friendly Version
06/02/17Nabriva Therapeutics to present data at ASM Microbe supporting ongoing Phase 3 clinical development program for lefamulin
Four abstracts demonstrate potential for lefamulin as a first-line, empiric treatment for patients with community-acquired bacterial pneumonia VIENNA, Austria and KING OF PRUSSIA, Pa., June 02, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that data will be prese... 
 Printer Friendly Version
05/23/17Nabriva Commences Previously Announced Tender Offer Related to the Proposed Redomicile of its Holding Company from Austria to Ireland
DUBLIN, Ireland , May 23, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc ("Nabriva Ireland") today commenced the previously announced tender offer related to the exchange of American depositary shares ("Nabriva AG ADSs") and common shares ("Nabriva AG Common Shares") of Nabriva Therapeutics AG (Nasdaq:NBRV) for ordinary shares of Nabriva Ireland (the "Exchange Offer").  Once the Exchange Offer is completed, Nabriva AG will become a subsidiary of Nabriva Ireland, and it is expec... 
 Printer Friendly Version
05/10/17Corrected - Nabriva Therapeutics Reports First Quarter 2017 Financial Results
- Expects top-line data from LEAP 1 CABP Phase 3 trial in third quarter 2017 and from LEAP 2 CABP Phase 3 trial in first quarter 2018Vienna, Austria / King of Prussia, PA, May 12, 2017 – Nabriva Therapeutics AG (NASDAQ: NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today provided a business and clinical development update and repor... 
 Printer Friendly Version
04/19/17Nabriva Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference
VIENNA, Austria and KING OF PRUSSIA, Pa., April 19, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Colin Broom, M.D., chief executive officer of Nabriva Therapeutics, will provide a company overview and business update at the Deutsche Bank 42nd Annual Health C... 
 Printer Friendly Version
04/17/17Nabriva Announces the Proposed Redomicile of its Holding Company from Austria to Ireland, by means of an Exchange Offer
VIENNA, Austria, April 17, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics Plc (NASDAQ:NBRV) ("Nabriva AG") announced that its supervisory board and management board approved the relocation of the holding company of Nabriva AG and its subsidiaries ("Nabriva Group") from Austria to Ireland (the "Redomiciliation Transaction"). The Redomiciliation Transaction will be effected by the exchange of American depositary shares ("Nabriva AG ADSs") and shares (the "Exchange Offer") of Nabriva Plc for share... 
 Printer Friendly Version
04/13/17Nabriva Therapeutics to present data at ECCMID supporting ongoing Phase 3 clinical development program for lefamulin
Nine abstracts support potential for lefamulin as a first-line, empiric treatment for patients with community-acquired bacterial pneumonia VIENNA, Austria and KING OF PRUSSIA, Pa., April 13, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics Plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that it will present data ... 
 Printer Friendly Version
04/11/17Nabriva Therapeutics Announces Enrollment Completion for LEAP 1, a Phase 3 Clinical Trial Evaluating Lefamulin in Community-Acquired Bacterial Pneumonia
VIENNA, Austria and KING OF PRUSSIA, Pa., April 11, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics Plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that it has completed enrollment in its first lefamulin evaluation against pneumonia (LEAP 1) Phase 3 clinical trial. LEAP 1, which is designed to assess the efficacy... 
 Printer Friendly Version
03/27/17Nabriva Therapeutics to Present at the Needham and Company 16th Annual Healthcare Conference
VIENNA, Austria and KING OF PRUSSIA, Pa., March 27, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics Plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Colin Broom, M.D., chief executive officer of Nabriva Therapeutics, will provide a company overview and business update at the Needham and Company 16th Annual He... 
 Printer Friendly Version
03/24/17Nabriva Therapeutics Provides Business and Development Update and Reports 2016 Financial Results
VIENNA, Austria and KING OF PRUSSIA, Pa., March 24, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics Plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today provided a business and clinical development update and reported its financial results for the year ended December 31, 2016. "For the last 12 months, we have been executing ... 
 Printer Friendly Version
02/27/17Nabriva Therapeutics to Present at the Cowen and Company 37th Annual Healthcare Conference
VIENNA, Austria and KING OF PRUSSIA, Pa., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics Plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Colin Broom, M.D., chief executive officer of Nabriva Therapeutics, will provide a company overview and business update at the Cowen and Company 37th Annual Healt... 
 Printer Friendly Version
02/08/17Nabriva Therapeutics to Participate in Two Investor Conferences in February
VIENNA, Austria, and KING OF PRUSSIA, Pa., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics Plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Colin Broom, M.D., Chief Executive Officer of Nabriva Therapeutics, will provide a company overview and business update at the following conferences in February.... 
 Printer Friendly Version
02/02/17Nabriva Therapeutics Confirms No Sample Size Adjustment Required for LEAP 1 Phase 3 Trial of Lefamulin in Community Acquired Bacterial Pneumonia
LEAP 1 top-line efficacy and safety data expected in 3Q17 VIENNA, Austria, and KING OF PRUSSIA, Pa., Feb. 02, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics Plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that following a blinded interim analysis, an independent committee recommended no sample size adjustment f... 
 Printer Friendly Version